Research and Articles

Login

Profiles and References

    Publications

    1. Oeriu S, Oeriu I, Winter D, Neuman MG: Influence of Folcisteine on the rat treated with CCl4. Revue Roumain de Biochimie, 4:53‑58, 1968.
    2. Pavlotzky M, Eshchar J, Neuman MG: Cimetidine and other H2 receptor blockers. Harefuah – J Israel Med Assoc, 95(7):219‑223, 11/1978. Hebrew. PubMed PMID: 31319.
    3. Feugelfeld L, Pavlotzky M, Neuman MG, Eshchar J: Gluten sensitive enteropathy in adults.Harefuah – J Israel Med Assoc, Oct 101(7-8):154‑156, 11/1981. Hebrew. PubMed PMID: 7333545.
    4. Neuman MG, Ishay JS, Eshchar J: Hornet (Vespa orientalis) venom sac extract
      caused hepatic injury in cats. Comp Biochem Physiol, 74C:469‑472, 1983. PubMed PMID: 6133694.
    5. Neuman MG, Eshchar J, Cotariu D, Ishay J, Barr‑Nea L: Hepatotoxicity of Hornet’s venom sac extract, after repeated in vivo and in vitro Acta Pharmacol Toxicol Scand, 53:314‑319, 1983.
    6. Eshchar J, Neuman MG, Pavlotzky M, Saibil F: Zollinger‑Ellison Syndrome ‑ prolonged Cimetidine administration and nasopharyngeal carcinoma ‑ a coincidence? Int J Tissue Reaction, 5 (4):411‑414, 1983. PubMed PMID: 6323340.
    7. Neuman MG, Eshchar J, Cotariu D, Ishay JS, Bar-Nea L. Hepatotoxicity of hornet’s venom sac extract, after repeated in vivo and in vitro envenomation. Acta Pharmacol Toxicol (Copenh). Oct;53(4):314-9, 1983. PubMed PMID: 6650181. 
    8. Neuman MG, Eshchar J, Cotariu D, Ben Sason R, Ziv E, Bar‑On H, Ishay JS:  Hepatotoxicity of Hornet’s venom sac extract in isolated perfused rat liver. Acta Pharmacol Toxicol, 56:133‑138, 1985, PubMed PMID: 2859733.
    9. Barr‑Nea L, Neuman MG, Eshchar J, Ishay JS: Histopathological changes in rat liver following repeated Vespinae envenomation. Liver, 5:326‑335, 1985. PubMed PMID: 4088006.
    10. Scapa E, Neuman MG, Eshchar J, Weisgarten S, Modai D: Beta hexosaminidase activity in chronic renal failure. Enzyme, 36:207‑211, 1986.
    11. Neuman MG, Eshchar J, Cotariu D, Barr Nea L, Ishay JS: Liver damage induced by Oriental hornet venom sac extract at the level of subcellular fraction. Clin Biochem, 20:85‑90, 1987. PMID: 3608144 The article was highlighted in the “Hepatology Elsewhere” [Zimmerman HJ. Hepatology: 7, 1384-1385, 1985].
    12. Neuman M. Relationships between chemical structure and adverse effects of antibacterial and antifungal agents. Chemoterapia. 6(4):299-305, 1987. PMID: 3652282.
    13. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 14(2):96-121, 1988. doi: 10.2165/00003088-198814020-00003. Erratum in: Clin Pharmacokinet 14(5), 1988. PMID: 3282749.
    14. Neuman MG, Ishay J, Zimmerman HJ, Eshchar J: Hepatotoxicity of the Oriental hornet venom. Harefuah- J Israel Med Assoc, 118(2):78‑80, 1990; PMID: 2312006.
    15. Neuman MG, Ishay J, Eshchar J: Bile acids in rat serum as indicators of hepatotoxicity by hornet venom. Proc Soc Exp Biol Med, 195:3‑6, 1990; PMID: 2236109.
    16. Neuman MG, Ishay J, Waron M, Scapa E, Eshchar J: Hepatotoxic effects of repeated administration of the Oriental hornet (Vespa orientalis) J Clin Lab Anal, 4(6):453‑456, 1990; PMID: 2149383.
    17. Scapa E, Neuman MG, Schwartz J, Magar J, Eshchar J: Serum beta‑N‑acetyl hexosaminidase (beta NAH) in the elderly. Hepato-Gastroenterology, 37 (Suppl 2): 100‑102, 1990; PMID: 2150663.
    18. Scapa E, Neuman, MG, Eshchar J: Inflammatory bowel disease and serum beta‑N‑acetyl-hexosaminidase. Enzyme, 43:146‑150, 1990; PMID: 2151316.
    19. Scapa E, Orda R, Neuman M, Sayfan J, Abramovici J, Eshchar J: Beta‑N‑acetyl hexosaminidase (B‑NAH) serum levels after endotoxin administration into the portal vein in the rat. Liver, 11 (1):39‑41, 1991; PMID: 1828523.
    20. Azcue M, Wesson D, Neuman MG, Pencharz P. What does bioelectrical impedance spectroscopy (BIS) measure? Basic Life Sci. 60:121-3, 1993 PMID: 8110090.
    21. Neuman MG, Koren G, Tiribelli C: In vitro, assessment of the ethanol- induced hepatotoxicity on Hep G2 cell line. Biochemical Biophysical Research Communications (BBRC), 197(2):932- 941, 1993.
    22. Neuman MG, Cameron RG, Shear NH, Bellentani S and Tiribelli C: Effect of tauroursodeoxycholate and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology, 109(2):555-563, 1995; PMID: 8688194.
    23. Shear NH, Malkiewicz I, Klein J, Randor S, Koren G, Neuman MG: Acetaminophen – induced toxicity to keratinocytes and to hepatocytes in vitro is diminished by Silymarin. Skin Pharmacology, 8(6):279-291, 1995; PMID: 8688194.
    24. Khoshoo V, Reifen R., Neuman MG, Griffits A, Pencharz PB: Effect of low and high fat, peptide – based diets on lean body mass and disease activity in adolescents with active Crohn’s disease. JPEN: J Parenteral & Enteral Nutrition, 20(6):401-405, 1996; PMID: 8950740.
    25. Cameron RG, Neuman MG, Blendis LM: Multivesicular stellate cells in primary biliary cirrhosis. Hepatology, 26(3):550-554, 1997; PMID: 9303481.
    26. Cameron RG, Neuman MG, Shear NH, Blendis LM: Multivesicular stellate cells in primary biliary cirrhosis-part 2. Hepatology, 26(4):819-822, 1997; PMID:9328298.
    27. Cameron RG, Neuman MG, Shear NH, Bellentani S, Katz G, Tiribelli C: Modulation of liver specific cellular response to ethanol in vitro in HepG2 cells.  Toxicology In Vitro, 12(2):111-122, 1998; PMID: 20654392.
    28. Shapiro L, Neuman M, Malkiewicz I, Shear N: Assessment of sulfonamide- induced hypersensitivity syndrome reactions with the use of a novel lymphocyte toxicity assay: preliminary results. Clin Invest Med 21:S15. A571, 1998.
    29. Neuman MG, Shear NH, Bellentani S, Tiribelli C: Role of cytokines in ethanol-induced hepatocytotoxicity in Hep G2 cells. Gastroenterology, 114(7):157-169, 1998; PMID: 9649471.
    30. Shear NH, Landau M, Malkiewicz I, Katz GG, Neuman MG: Ethanol-modulated cytokine production and expression in skin cells exposed to Methotrexate. Skin Pharmacol Applied Skin Physiol 12(1-2):64-78, 1999; PMID: 10325585.
    31. Neuman MG, Shear NH, Cameron RG, Katz GG and Tiribelli C: Ethanol-induced apoptosis in vitro. Clin Biochem, 32,7:547-555, 1999; PMID: 10614717.
    32. Cameron RG and Neuman MG: Novel morphologic findings in alcoholic liver disease. Clin Biochem, 32,7:579-584, 1999; PMID: 10614721.
    33. Neuman MG, Benhamou JP, Martinot M, Boyer N, Shear NH, Malkiewicz I, Katz GG, Suneja A, Singh S, Marcellin P. Predictors of sustained response to alpha-interferon therapy in chronic hepatitis C. Clin Biochem. 32(7):537-45, 1999. PubMed PMID: 10614716.
    34. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH: Inducers of Cytochrome P450 2E1 enhances methotrexate-induced hepatocytotoxicity. Clin Biochem, 32,7:519-536, 1999; PMID: 10614715.
    35. Neuman MG, Malkiewicz IM, Shear NH: A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem, 33,7:517-524, 2000. PMID: 11124336.
    36. Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim, Boyer N, Martinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem, 34,3:173-182, 2001; PMID: 11408014.
    37. Cameron RG, Blendis LM, Neuman MG. Perisinusoidal accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem, 34,3:195-201, 2001; PMID:11408017.
    38. Katz GG, Shear NH, Malkiewicz IM, Valentino K, Neuman MG. Signaling for ethanol-induced apoptosis and repair in vitro. Clin Biochem, 34,3:218-235, 2001; PMID: 11408020.
    39. Popat A, Shear NH, Stewart M, Thomson S, Malkiewicz I, Neuman MG: The hepatotoxicity of Callilepis laureola, a South African herbal medicine, in HepG2 cells in vitro. Clin Biochem, 34(3):219-227, 2001; PMID: 11408021.
    40. Neuman MG, Blendis LM, Shear NH, Malkiewicz IM, Ibrahim A, Katz GG, Sapir D, Halpern Z, Brill S, Peretz H, Magazinik S, Konikoff FM. Cytokine network in non responding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon gamma, ribavirin and ursodeoxycholate. Clin Biochem, 34 (3):183-188, 2001; PMID: 11408015.
    41. Neuman MG, Shear NH, Jacobson-Brown PM, Katz GG, Neilson HK, Malkiewicz IM, Cameron RG, Abbott F: CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin Biochem, 34(3):211-218, 2001; PMID: 11408019.
    42. Krivoy N, Struminger L, Bendersky R, Aviv I, Neuman MG, Pollack S: Rifampin-induced thrombocytopenia and hemolysis: diagnosis by a novel in vitro lymphocyte toxicity assay. The Israel Med Association J., 3:536-537, 2001, PMID: 11791425.
    43. Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, Marcellin P: Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine, 17(2): 108-117, 2002, PMID:11886178.
    44. Neuman MG, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, Katz G, Lindor K: Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatology, 17(2):196-202, 2002, PMID: 11966951.
    45. Popat A, Shear NH, Malkiewicz I, Thomson S, Neuman MG: Mechanism of Impila (Callilepis laureola)-induced cytotoxicity in Hep G2 cells. Clin Biochem 35(1):57-64, 2002, PMID: 11937079.
    46. Neuman MG, Thompson S, Malkiewicz IM, Popat A, Shear NH: Impila. Clin Biochem. 05/2002; 35(3):179–180.
    47. Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Bourliere M, Katz GG, Shear NH, Marcellin P: Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepatitis 9(2):134-40, 2002; PubMed PMID: 11876796.
    48. Neuman MG, Thompson S, Malkiewicz IM, Popat A, Shear NH: Response to the editor for Mechanism of Impila (Callilepis laureola) – induced cytotoxicity in Hep G2 cells. Clin Biochem, 35(3):179-80, 2002.
    49. Neuman MG, Cameron RG, Haber JA, Katz GG, Blendis LM: An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis. Liver, 22 (3):235-244, 2002, PMID: 12100574.
    50. Neuman MG, Haber JA, Malkiewicz IM, Cameron RG, Katz GG, Shear NH: Ethanol signals for apoptosis in cultured skin cells. Alcohol 26(3):179-90, 2002, PMID: 12057780.
    51. Neuman MG, Benhamou JP, Ibrahim A, Malkiewicz I, Spircu T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Bourliere M, Marcellin P: Serum tumor necrosis factor levels in chronic hepatitis C. Rom J Gastroenterol., 11(1):5-17, 2002, PMID:12145664.
    52. Neuman MG: Synergetic signaling for apoptosis in vitro by ethanol and acetaminophen. Alcohol, 27(2):89-98, 2002, PMID: 12106828.
    53. Neuman MG, Benhamou JP, Ibrahim A, Malkiewicz IM, Spircu T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Bourliere M, Marcellin P: Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. Rom J Gastroenterology, 11(2):97-103, 2002.
    54. Neuman MG, Malkiewicz IM, Phillips EJ, Rachlis A, Ong D, Yeung E, Shear NH: Monitoring adverse drug reactions to sulphonamide antibiotics in human immunodeficiency virus infected individuals. Therapeutic Drug Monitoring, 24(6):728-736, 2002, PMID: 12451289.
    55. Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH: Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Safety, 26(3): 187-95, 2003, PMID: 12580647.
    56. Ben-Ari Z, Schmilovitz-Weiss H, Belinki A, Pappo O, Sulkes J, Neuman M, Kaganovsky E, Kfir B, Tur-Kaspa R, Klein T: Circulating soluble cytochrome c in liver disease as a marker of apoptosis. Am J Gastroenterology, 254:168-175, 2003, PMID: 12859698.
    57. Shaked Y, Cervi D, Neuman M, Chen L, Klement G, Michaud CR, Haeri M, Pak BJ, Kerbel RS, Ben-David Y: The splenic microenvironment is a source of pro-angiogenesis/ inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood. 105(11), 4500-4507, 2005, PMID: 15701719; PMCID: PMC1895028.
    58. Krivoy N, Taeri M, Neuman MG: Antiepileptic drug-induced hypersensitivity syndrome reactions mechanisms. Current Drug Safety, 1(3), 289-299, 2006; PMID:18690940.
    59. Neuman MG, Benhamou JP, Marcellin P, Valla DC, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron R, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z. Cytokine-chemokine signature in chronic hepatitis C patients. Transl Res, 149(3), 126-136, 2007, PMID: 17320798.
    60. Neuman MG, Shear NH, Malkiewicz IM, Taeri M, Shapiro LE, Krivoy N, Haber J, Gomez M, Fish J, Cartotto R, Cohen L: Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides.Transl Res.149(5):243-53, 2007, PMID: 17466923.
    61. Neuman MG, Nicar M: Ibuprophen-induced toxic epidermal necrolysis. Transl Res. 149(5):254-259, 2007, PMID: 17466924.
    62. Neuman MG, Jia A, Steenkamp V: Senecio latifolis-induced hepatotoxicity in vitro. Can J Physiol Pharmacol, 85(11), 1063-1075, 2007, PMID: 18066108.
    63. Oz H, Chen T, Neuman MG: Methionine deficiency and hepatic injury in a dietary steatohepatitis model. Digestive Dis Sc, 53(3), 767-776, 2008, PMID: 17710550; PMC2271115.
    64. Neuman MG, Shear NH, Malkiewicz IM, Lee A., Kesas M, Cohen L: Predicting possible Zonisomide-induced hypersensitivity syndrome reactions; mechanisms and diagnostic. Exp Dermatology, 17(12), 1045-1051, 2008, doi: 10.1111/j.1600-0625.2008.00748.x. Epub 2008 Jul 7. PMID: 18637135.
    65. Neuman MG, Winkler R: Veno-occlusive disease of the liver Induced by traditional herbal medicine. Roumanian J. Rev Hepatol, 4, (2)3, 7-9, 2008.
    66. Oz HS, Chen TS, Neuman M: Nutrition intervention: a strategy against systemic inflammatory syndrome. JPEN J Parenter Enteral Nutr; 33(4):380-9, 2009, doi: 10.1177/0148607108327194. Epub 2009 Apr 14.PMID: 19380752; PMC3063840.
    67. Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio    FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A: Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res. 154(4):194-201, 2009. doi: 10.1016/j.trsl.2009.06.007. PMID: 19766963.
    68. Neuman MG, Oruña L, Coto G, Lago G, Nanau RM, Vincent M. Hyaluronic acid  signals for repair in ethanol-induced apoptosis in cultured skin cells in vitro Clin Biochem,  43 (10-11):822-6, 2010. doi:1016/j.clinbiochem.2010.04.005. PMID: 20398644.
    69. BaniHani M, Neuman M, Stefenel A, Hwang PA. In-vitro predictors of severe   hypersensitivity to aromatic anti-epileptic drugs. Clinical Neurophysiology – 01/2011; 122(1).
    70. Neuman MG, Oruña L, Nanau RM, Coto G.  In vitro anti-inflammatory effects of hyaluronic acid in ethanol-induced damage in skin cells. J Pharm Pharmaceutical Sc, 14(3), 425-437, 2011.
    71. Neuman MG, Schmilowitz-Weiss H, Hilzenrat N, Bourliere M, Marcelin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen, L: Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol, special issue on Non-Alcoholic Hepatitis, doi:10.1155/2012/231210. 2012.:231210; PMID:22530132; PMCID: PMC3296182.
    72. Neuman MG, Cohen L, Nanau MR, Hwang P: Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res, (J Clinical and Lab Medicine), 159 (5), 397-406, 2012; DOI 101016/j. trsl 201201.004, PMID: 22500513.
    73. Neuman MG, McKiney K, Malkiewicz I, Nanau R, Moussa G, Mazzulli T, Kong V. Drug-induced severe adverse reaction enhanced by Human Herpes Virus-6 reactivation. Transl Res. 2013;161(5):430-40. doi: 10.1016/j.trsl.2012.12.012. PMID: 23333110.
    74. Neuman MG, Nanau RM, Shekh-Ahmad T, Yagen B, Bialer M. Valproic acid derivatives signal for apoptosis and repair in vitro. Clin Biochem. 46, 15, 1532-1537, 2013. pii: S0009-9120(13)00336-6. doi:10.1016/j.clinbiochem.2013.07.003, PMID: 23868021.
    75. Neuman MG, Maor Y, Cohen L, Hilzerat N. Inflamasome and Free Light Chain in asymptomatic transaminasemia, Gastroenterology, 2013.
    76. Cooper C, Shafran S, Greenbloom S, Enns R, Farley F, Hilzerat N, Williams M, Elkashab M, Abadir N, Neuman MG. Single dose Infliximab in Hepatitis C genotype 1 naïve patients with high serum tumor necrosis factor alpha does not influence efficacy of Pegylated Interferon alpha-2b/ Ribavirin therapy. Canadian J. Gastroenterology and Hepatology, J. Canadien de Gastroenterologie et Hepatologie, 28,1, 35-40, 2014; PMID:24212915; PMCID: PMC4071902.
    77. Neuman MG, Cohen L, Opris M, Nanau RM, Jeong H. Hepatotoxicity of  Pyrrolizidine Alkaloids. J Pharm Pharm Sci. 2015;18(4):825-43. PubMed PMID:  26626258.
    78. Roerecke M, Nanau R, Rehm J, Neuman M. Ethnicity matters: a systematic   review and meta-analysis of the non-linear relationship between alcohol consumption and prevalence and incidence of hepatic steatosis. EBioMedicine. 2016 Jun;8:317-30.doi: 10.1016/j.ebiom.2016.04.023. PubMed PMID: 27428441; PubMed Central PMCID:PMC4919723.
    79. Roerecke M, Rehm J, Neuman M. Alcohol and steatosis: The Japanese paradox     Authors’ reply. EBioMedicine. 2016 Jun;8:25. doi: 10.1016/j.ebiom.2016.05.022.PubMed PMID: 27428413; PubMed Central PMCID: PMC4919571.
    80. Neuman MG, Voiculescu M, Nanau RM, Maor Y, Melzer E, Cohen LB, Opris M,Malnick S. Non-alcoholic steatohepatitis: clinical and translational research. J Pharm Pharm Sci. 2016;19(1):8-24. doi: 10.18433/J3F61F. PubMed PMID: 27096691.
    81. Roerecke M, Rehm J, Neuman M. Errors in meta-analysis on prevalence of non-alcoholic fatty liver disease (NAFLD). Hepatology. 2016 Mar 31. doi: 10.1002/hep.28585. [Epub ahead of print] PMID: 27038346.
    82. Neuman MG, Cohen LB, Steenkamp V. Pyrrolizidine alkaloids enhance alcohol-induced hepatocytotoxicity in vitro in normal human hepatocytes. Eur Rev Med Pharm Sci, Special issue on drug-induced hepatotoxicity, 2017; 21(1 Suppl):53-68. PubMed PMID: 28379594.
    83. Malnick S, Maor Y, Melzer E, Ziv-Sokolowskaia N, Neuman MG. Severe hepatotoxicity linked to denosumab. Eur Rev Med Pharmacol Sci, Special issue on Drug-induced hepatotoxicity, 2017;21(1 Suppl):78-85. PubMitatiaed PMID: 28379592.
    84. Neary J, Goodwin SE, Cohen LB, Neuman MG. Alcohol misuse link to POEMS syndrome in a patient. Cancers (Basel). 2017 Sep 23;9(10). pii: E129. doi: 10.3390/cancers9100129. PubMed PMID: 28946631; PubMed Central PMCID:  PMC5664068.
    85. Neuman MG, Cohen LB, Malnick S. Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma. Chem Biol Interact., 2020 May 25;323:109054. doi: 10.1016/j.cbi.2020.109054. Epub 2020 Mar 23.
    86. Ostrovsky V., Malnick S., Ish-Shalom S, Ziv Sokolowskaia N., Yosepovich A., Neuman, MG. Denosumab-induced immune hepatitis. Biomedicines, special issue: Experimental and Research in Liver Disease, 2021, 9, 76. https://doi.org/10.3390/ biomedicines9010076.
    87. Maor Y., Ergaz D., Malnick S.D.H.; Melzer E., Neuman, M.G. Liraglutide-Induced hepatotoxicity. Biomedicines, Experimental and Research in Liver Disease, 2021, 9, 106. https://doi.org/10.3390/biomedicines9020106.
    88. Neuman, M.G, Mueller J, Mueller S. Non-invasive biomarkers of liver inflammation and cell death in response to alcohol detoxification. Front. Physiol. Section Gastrointestinal Sciences, 2021, 7,12:678118, doi: 10.3389/fphys.2021.678118 PMID: 34305638; PMCID: PMC8292967.
    89. Neuman, M.G., Cohen, L.B. Inflammation and liver cell death in patients with hepatitis C viral Infection. Curr. Issues Mol. Biol. 2021, 43, 2022–2035. https://doi.org/ 10.3390/cimb43030139.

              Invited Editorial Articles and Reviews:

                1. Eshchar J, Pavlotzky M, Neuman MG: Cimetidine ‑ Update. Harefuah – J Israel Med Assoc, 99:383‑389, 1980.
                2. Neuman MG: H2 receptors. J Israel Med Assoc, 106(6): 239-242, 1983.
                3. Neuman MG: Beta-hexosaminidase as a macrophage marker. Harefuah, 108(2):86-89, 1985.
                4. Azcue M, Wesson D, Neuman MG, Pencharz P. What does bioelectrical impedance spectroscopy (BIS) measure? Basic Life Sci. 1993;60:121-3. PMID: 8110090
                5. Neuman MG: Model for in vitro J. Drug Information Assoc, 3, 26-35, 1998.
                6. Neuman MG: First International Symposium on the molecular pathology and clinical aspects of the inflamed liver: alcohol and cytokines. Clinical and investigative medicine. Médecine clinique et experimentale 21(6):283-6, 1998, PMID: 9885764.
                7. Neuman MG: Cytokines and Inflamed Liver. Clin Biochem, 33: 601-605, 1999.
                8. Neuman MG: Mechanism of Alcoholic Liver Disease. Clin Biochem, 34,3, 163-167, 2001.
                9. Neuman MG: Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci, 38(2): 109-66, 2001, PMID: 11347718.
                10. Neuman MG, Brenner DA, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, Garaud JJ, Poynard T, Katz GG, Cameron RG, Shear NH, Gao B, Takamatsu M, Yamauchi M, Ohata M, Saito S, Maeyama S, Uchikoshi T, Toda G, Kumagi T, Akbar SMF, Abe M, Michitaka K, Horiike N, Onji M. Mechanisms of alcoholic liver disease: cytokines.  Alcohol Clin Exp Res,25 (5) Suppl ISBRA):251S-253S, 2001, PMID: 11391079.
                11. Jacobson Brown P, Neuman MG: New treatments for chronic hepatitis C. Digestive Disease Week 2000 conference report: Can J Clin Pharmacol, 8(2): 67-71, 2001, PMID: 11493933.
                12. Jacobson-Brown P, Neuman MG: Immunopathogenesis of hepatitis C viral Infection: Th1/Th2 responses and the role of cytokines. Clin Biochem, 34,3:167-171, 2001, PMID: 11408013.
                13. Neuman MG: Metabolic effects and drug interactions provoked by certain vegetables: grapefruit, St. John’s wort and garlic. Presse Med. 21;31(30):1416-22, 2002.
                14. Neuman MG: Apoptosis in liver disease. Rom J Gastroenterology, 11(1): 3-7, 2002, PMID: 12096306..
                15. Ibrahim A. Katz GG. Neuman MG: Tumor necrosis factor alpha as a noninvasive marker of liver inflammation in patients with viral hepatitis C. Am Clin Lab, 21(7):12-5, 2002.
                16. Ibrahim A, Neuman MG: Cytokines in viral hepatitis C, role of treatment. Rev Rom Hepatology, 2(2), 5-9, 2002, PMID: 12380024.
                17. Molina P, McClain C, Valla D, Guidot D, Diehl AM, Lang C, Neuman MG: Molecular pathology and clinical aspects of alcohol induced tissue injury.  Alcoholism: Clin and Exper Research, 26(1):120-128, 2002, PMID: 11821662.
                18. Neuman MG, Katz G, Malkiewicz I, Mathurin P, Tsukamoto H, Adachi M, Ishii H, Colell A, García-Ruiz C, Fernández-Checa JC, Casey CA: Alcoholic liver injury and apoptosis: synopsis of the symposium held at ESBRA 2001: 8th Congress of the European Society for Biomedical Research on Alcoholism, Paris, September 16, 2001, Alcohol, 11, 28(2), 117-128, 2002, PMID: 12457943.
                19. Jacobson-Brown P, Neuman MG: Colon polyps and cytokines: Emerging Immunological Mechanisms. Rom J of Gastroenterology, 12, 3, 207-214, 2003, PMID: 14502322..
                20. Neuman M: Cytokines in alcoholic liver. Alcohol Research & Health, 27(4):307-316, 2003.
                21. Jacobson-Brown P, Neuman MG: Colorectal polyposis and immune-based therapies. Can J of Gastroenterology, vol 18(4):239-249, 2004, PMID: 15054500.
                22. Neuman MG, Colin P, Angulo P, Lindor K. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. Immunology 2004, International Proceeedings of the 12 International Meeting of Immunology and 4 Annual Conference of FOCIS, Montreal, Canada, Medimond, 187-191, 2004.
                23. Keys S, Hill G, Collier C, Hoffman B, Young E, Vandenberghe H, Moses G, Allen L, Tomalty C, Grey V, Chan PC, Neuman MG: Estimating GFR.Current Laboratory Practice, 8, 2004.
                24. Keys S, Hill G, Collier C, Hoffman B, Young E, Vandenberghe H, Moses G, Allen L, Tomalty C, Grey V, Chan PC, Neuman MG: Biochemical testing in diabetes: Hemoglobin A1c.Current Laboratory Practice, 7, 2004.
                25. Neuman MG: Signalling for inflammation and repair in inflammatory bowel disease. J Gastroenterology and Liver Dis,13(4), 309-316, 2004, PMID:15624029.
                26. Neuman MG: Personalized medicine, preventing and treating adverse drug reactions. Biotechnology Focus, 13-16 & 41, April 2006.
                27. Neuman MG: Markers of fibrosis in liver disease. Rom J Hepatology, 2, 3, 56-58, 2006.
                28. Neuman MG, Monteiro M, Rehm J Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 41(10-12):1395-463, 2006, PMID: 17002989.
                29. Neuman MG. Cytokine – chemokines modulate fibrosis in alcoholic hepatitis. Rom J Hepatology, 3, 2, 19-34, 2007
                30. Neuman MG Immune dysfunction in inflammatory bowel disease Transl Res, 149(4):173-186, 2007, PMID: 17383591.
                31. Neuman MG, Sha K, Esguerra R, Winkler RE, Cooper C, Hilzenrat N, Wise J, Zakhari S, Seth D, Gorrell M, Haber P, McCaughan GW, Leo MA, Lieber CS, Voiculescu M, Buzatu E, Ionescu C, Dudas J, Saile B, Ramadori G: Inflammation and repair in viral hepatitis C. Dig Dis Sc; 53(6); 1468-1487, 2008; PMID: 17994278.
                32. Voiculescu M, Winkler RE, Moscovici M, Neuman MG: Chemotherapies in advances hepatocellular carcinoma from laboratory to clinic. J Gastrointestinal Liver Dis, 17 (3), 315-322, 2008; PMID: 18836626.
                33. Rehm J, Samokhvalow AW, Neuman MG, Room R, Parry CD, Lönnroth K, Patra J, Poznyak V, Popova S: The association between alcohol use, alcohol use disorders and tuberculosis (TB).  A systematic review. BMC Public Health, Dec 5, 9:450, 2009; doi: 10.1186/1471-2458-9-450; PMID: 19961618; PMCID: PMC2796667.
                34. Neuman MG, Steenkamp V: Toxicity profile of pyrrolizidine alkaloid–containing medicinal plants: emphasis on Senecio species Indian J of Biological Sciences, International J Biomedical and Pharmaceutical Sciences 3 (1): 13, 26-30 104-108 for IJBPS-11 and 13-2009.
                35. Seth D, D’Souza El-Guindy N.B., Apte M, Mari M, Dooley S, Neuman M.G, Haber PS, Kundu GC; Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A , Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC; Meyer B, Meindl-Beinker NM. Alcohol, signaling and ECM turnover Alcoholism: Clin Exp Res, 34(1):4-18. doi : 10.1111/j.1530-0277.2009.01060.x; PMID:19860812.
                36. Shuper P, Neuman M, Kanteres F, Baliunas D, Rehm J, Causal considerations on alcohol and HIV/AIDS a systematic review. Alcohol Alcohol, 45, (2), 159-166,2010; doi: 10.1093/alcalc/agp091; PMID: 20061510.
                37. Nanau R.M., Neuman M Ibuprofen-induced hypersensitivity syndrome reactions. Translational Research, 155 (6),275-293, 2010. Jun. doi: 10.1016/j.trsl.2010.01.005; PMID: 20478543.
                38. Wong SHY, Happy C, Blinka D, Gock S, Jentzen JM, Donald Hon. J, Coleman H, Jortani SA, Lucire Y, Morris-Kukoski CL, Neuman MG, Orsulak PJ, Sander T, Wagner MA, Wynn JR, Wu AHB, Yeo KTJ. From personalized medicine to personalized justice: The promises of translational pharmacogenomics in the justice system. Pharmacogenomics, 11, 6, 731-737, 2010; doi: 10.2217/pgs.10.63; PMID: 20504247.
                39. Neuman MG. Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery. Dig. Dis. Sc. 2012, 57(6):1430-1; DOI: 10.1007/s10620-012-2120-9.
                40. Nanau MR and Neuman MG. Metabolome and inflammasome in inflammatory bowel disease. Transl Res, 160 (1):1-28, Special Issue on Inflammatory Bowel Disease and Metabolomics, 2012; 1-23; doi. 10.1016/j.trl.2011.08.006; PMID: 22687960.
                41. Neuman MG, Nanau RM. Inflammatory bowel disease role of diet, microbiota, life style. Translational Research, 160 (1):29-44, Special Issue on Inflammatory Bowel Disease and Metabolomics, 2012; . doi: 10.1016/j.trsl.2011.09.001.
                42. Neuman MG and Nanau RM. Single nucleotide polymorphisms in inflammatory bowel disease. Transl Res, 156, Special Issue on Inflammatory Bowel Disease and Metabolomics, 2012 Jul;160(1):45-64. doi: 10.1016/j.trsl.2011.10.006; PMID: 22687962.
                43. Nanau RM, Neuman MG. Nutritional and probiotic supplementation in colitis models, Dis. Sci., 57,(11):2786-2810, 2012, (DOI) 10.1007/s10620-012-2284-3; PMID: 22736018.
                44. Neuman MG, Schneider M, Nanau RM, Parry C. Alcohol consumption, progression of the disease and comorbidities and responses to antiretroviral medication in people living with HIV. AIDS Res Treat, 2012:751827. DOI: 10.1155/2012/751827. PMID: 22496971; PMCID: PMC3310201.
                45. Schneider M, Neuman MG, Chersich M, Parry C: Alcohol and HIV medication a deadly cocktail. J of AIDS and Clin Research. Special Issue: Risk behaviour: HIV/AIDS, ISSN 2155-6113; 2012, dx.doi.org.10.4172/2155-6113 S1.005; PMID: 22496971; PMCID: PMC3310201.
                46. Neuman MG, Schneider M, Nanau RM, Parry C: Hepatic, gastrointestinal and pancreatic adverse reactions of HAART: role of alcohol and HIV medication. Int. J. Hepatology, doi:10.1155/2012/760706; special issue on Multiple Aspects of Non-alcoholic Hepatitis, 2012; PMID: 22506127; PubMed Central PMCID: PMC3312274.
                47. Schneider M, Chersich M, Neuman MG, Parry C: Alcohol consumption and HIV/AIDS: the neglected interface. Addiction 2012;107(8):1369-71. doi: 10.1111/j.1360-0443.2012.03824.x; PMID: 22703162.
                48. Pritchett J, Nanau RM, Neuman MG: The link between hypersensitivity syndrome reaction development and human herpes virus-6 reactivation. Int J Hepatology, special issue on multiple aspects of non-alcoholic hepatitis, 36-46, 2012, Article ID 723062, doi:10.1155/2012/723062, 2012; PMID:22666603; PubMed Central PMCID: PMC3362035.
                49. Neuman MG. Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery. Dig Dis Sci. 2012;57(6):1430-1. doi: 10.1007/s10620-012-2120-9. Editorial article Comment on  Dig Dis Sci. 2012 Jun;57(6):1554-61.
                50. Neuman MG, Hilzenrat N, Cohen L, Winkler RE, Nanau R. Multiple factors involved in nonalcoholic hepatitis pathogenesis. Int J Hepatol. 2012;2012:429805. doi: 10.1155/2012/429805. Editorial article PMID: 23320181; PMCID: PMC3539328.
                51. Neuman MG. Multiple factors involved in liver inflammation- markers of inflammation and fibrosis of the liver. Canadian Society of Clinical Chemist- La Societe Canadienne des Clinico-chimiste, 54 No. 5, 2012 ISSN 0826-1024.
                52. Binazon O, Dubois-Gauche A, Nanau RM, Neuman MG. Efficacy and safety of platelet inhibitors. J Pharm Pharm Sci. 2013;16(1):1-39; PMID: 23683603.
                53. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 46, 15, 1323-1338, 2013. pii: S0009-9120(13)00289-0. doi: 51.10.1016/j.clinbiochem.2013.06.012. PMID: 23792104.
                54. Neuman M.G., French S.W., Casey C.A., Kharbanda K., Nanau R.M., Rasineni K, McVicker B.L., Kong V., Donohue Jr. T.M. Changes in the pathogenesis of alcohol-induced liver disease – Preclinical studies. Exp Mol Pathol 95 (3) 2013, 376-384, DOI information: 10.1016/j.yexmp.2013.10.006; PMID: 24161955.
                55. Neuman M.G., Cohen L, Zakhari S, Nanau R.M., Isip R, Mueller S, Schneider M, Parry C, Seitz H.K. Alcoholic liver disease: a synopsis of the Charles Lieber’s Memorial Symposia 2009-2012. Alcohol Alcohol.49 (4), 373–380, 2014, doi: 10.1093/alcalc/agu021; PubMed PMID: 24816574; PubMed Central PMCID: PMC4072899.
                56. Cohen L, Nanau RM, Delzor F, Neuman MG. Biological therapies in inflammatory bowel disease. Trans Res. 163 (6), 533-556, 2014. pii: S1931-5244(14)00003-6. doi:10.1016/j.trsl.2014.01.002; PMID: 24467968.
                57. Nanau RM, Delzor F, Neuman MG. Efficacy and safety of prasugrel in acute coronary syndrome patients. Clin Biochem 47 (7-8) 2014, 516-528 Mar 21. doi: 1016/j.clinbiochem.2014.03.005; PMID:24657510.
                58. Neuman MG, French SW, French BA, Seitz HK, Mueller S, Cohen LB, Osna NA, Kharbanda KK, Seth D, Bautista A, Thompson KJ, McKillop IH, Kirpich IA, McClean CJ, Bataller R, Nanau RM, Voiculescu M, Opris M, Shen H, Tillman B, Li J, Liu H, Malnick S: Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathology, 2014;97(3):492-510. 10.1016/j.yexmp.2014.09.005.
                59. Neuman M.G, Cohen LB, Nanau RM. Biomarkers in non-alcoholic fatty liver disease. Can J. Gastroenterology and Hepatology. J. Canadien de Gastroenterologie et Hepatologie, 28 (11), 607-614, 2014.
                60. Nanau RM, Cohen LB, Neuman MG: Risk of infections of biological therapies in with accent on inflammatory bowel disease. J. Pharm Pharm Sci. 17(4) 485 – 528, 2014.
                61. Voiculescu M, Nanau RM, Neuman M.G: Biomarkers of nonalcoholic fatty liver leading to hepatocellular carcinoma. J. Gastrointestin Liver Dis., 23, 4, 425-429, 2014, URL: http://www.jgld.ro/2014/3/15; DOI: http://dx.doi.org/10.15403/jgld.2014.1121.234.bna; PMID: 25532002.
                62. Neuman M.G, Cohen LB, Nanau RM: Non-medicinal interventions in non-alcoholic fatty liver disease. Can J of Gastroenterology & Hepatology, CJGH-2014-347.
                63. Nanau RM, Neuman MG. Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci. 2014.17(3):324-61; PMID: 25224347.
                64. Neuman M.G, Nanau RM, Sachez-Oruna L, Coto G. Hyaluronic acid and wound healing. Pharm Pharm Sci. 18(1) 53 – 60, 2015. PubMed PMID: 25877441.
                65. Neuman MG, Cohen LB, Nanau RM: Quinolones-induced hypersensitivity reactions. Clinical Biochemistry, 2015, 48, (10–11), 716-739. DOI information: 10.1016/j.clinbiochem.2015.07.019; PubMed PMID: 25895484.
                66. Nanau RM, Neuman MG: Biomolecules and Biomarkers Used in Diagnosis of Alcohol Drinking and in Monitoring Therapeutic Interventions, Biomolecules 2015, 5(3), 1339-1385; doi:3390/biom5031339, Special Issue Multi-Organ Alcohol-Related Damage: Mechanisms and Treatment), http://www.mdpi.com/journal/biomolecules/special_issues/alcohol-damage.
                67. Neuman MG, Maor Y, Nanau RM, Melzer E, Mell H, Opris M, Cohen L, Malnick S. Alcoholic liver disease: role of cytokines Biomolecules 2015, 28,5(1), 1339-1385; doi:3390/biom5031339, Special Issue Multi-Organ Alcohol-Related Damage: Mechanisms and Treatment), and 2023-34. doi: 10.3390/biom5032023. Review. PubMed PMID: 26343741; PubMed Central PMCID: PMC4598786.http://www.mdpi.com/journal/biomolecules/special_issues/alcohol-damage.
                68. Neuman M.G, Cohen LB, Nanau RM: Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochemistry, 2016, 49(3), 302-315; pii: S0009-9120(15)00280-5. doi: 10.1016/j.clinbiochem.2015.07.019. PubMed PMID: 26188920.
                69. Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen L, Kharbanda KK, Osna NA, Ganesan M,  Thompson KJ, McKillop IH, Bautista A, Bataller R, French SW: Alcoholic liver disease, clinical and translational research: Exp Mol Pathol, 2015, 99, 3, 596-610.  S0014-4800 (15)00185-9; doi:10.1016/j.yexmp.2015.09.001. PubMed PMID: 26342547.
                70. Neuman MG, Cohen LB, Opris M, Nanau RM, Hyunjin J: Hepatotoxicity of pyrrolizidine alkaloids, Pharm Pharm Sci., Special issue on Natural Products, 18 (4). 825-843, 2015. PubMed PMID:26626258.
                71. Neuman MG, Voiculescu M, Maor Y, Nanau RM, Melzer E, Opris M, Cohen LB, Malnick S: Non- alcoholic liver disease. J Pharm Pharm Sci., 2016, 19 (1): 8-24. doi: 10.18433/J3F61F. PubMed PMID:27096691.
                72. Neuman MG,French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PS, Schrum LW, Donohue Jr. TM,  Kharbanda K, Cruz M,  Opris M.  Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Experimental and Molecular Pathology, DOI: 10.1016/j.yexmp.2017.01.003.
                73. Oz HS, Yeh SL, Neuman MG. Gastrointestinal inflammation and repair: role of microbiome, infection and nutrition. Gastroenterology Research and Practice 2016, Article ID 6516708, 3 pages Editorial
                74. Dumitrascu D and Neuman MG. Non alcoholic fatty liver disease, an update of diagnosis. Cluj Medical, 2018. DOI: 10.15386/cjmed-993
                75. Menashi S, Cohen LB, Neuman MG. Obesity and non-alcoholic fatty liver -Therapies in Ayurvedic Medicines. OBM Integrative and Complementary Medicine Herbal Medicines for the Treatment of Metabolic Syndrome, Lidsen Pub. Inc.,        2018, vol. 3, issue 1, 1-26.  doi:10.21926/obm.icm.1801002
                76. Neuman MG: Biomarkers in drug-induced liver Injury. Ther Drug Monitoring,      41(2):227-234, April 2019.doi: 10.1097/FTD.0000000000000610
                77. Teschke R, Eickhoff A, Brown AC, Neuman MG, Schulze J. Diagnostic    biomarkers in liver injury by drugs, herbs, and alcohol: tricky dilemma after EMA correctly and officially retracted letter of support. Int J Mol Sci. 2020;21(1)., pii: E212. doi: 10.3390/ijms21010212. Review. PubMed PMID: 31892250; PubMed Central PMCID: PMC6981464.
                78. Neuman MG, Seitz HK, French SW,  Malnick S , Tsukamoto H,  Cohen LB,  Hoffman P, Tabakoff B,  Fasullo M,  Nagy LE, Tuma P, Schnabl B, Mueller S, Groebner JL, French A. B,  Yue J, Afifiyan N , Mendoza , Tillman B, Vitocruz E, Harrall K,  Saba L, Opris M. Alcoholic hepatitis, links to brain and microbiome: echanisms, clinical and experimental research. Biomedicines 2020, 8(3), 63; https://doi.org/10.3390/biomedicines8030063 Special Issue Alcoholic Liver Disease: Diagnostics and Therapeutics PMCID: PMC7148515; PMID: 3219742410.3390/biomedicines8030063.
                79. Neuman MG, Malnick S, Chertin L. Gamma glutamyl transferase – an underestimated marker for cardiovascular disease and the metabolic syndrome. J Pharm Pharm Sci. 2020;23(1):65-74. doi: 10.18433/jpps30923.
                80. Cohen L, Neuman MG. Cannabis and the gastrointestinal tract. J Pharm Pharm Sci. 2020;23:301-313. doi: 10.18433/jpps31242. PMID: 32762830
                81. Malnick S, Mildiner S, Neuman MG: Obeticholic acid for treatent of NAFLD- a drug in search of a disease. HepGastro, 2020, 2, 133-137.
                82. Malnick SDH, Abdullah A, Neuman MG: Checkpoint inhibitors and hepatotoxicity. Biomedicines, Special issue Experimental and Research in Liver Disease 2021, 9, 101. https://doi.org/10.3390/biomedicines9020101.
                83. Teschke R, Neuman MG, Liangpunsakul S, Seitz HK. Alcoholic liver disease and the co-triggering role of MEOS with its CYP 2E1 catalytic cycle and ROS. Arch of Gastroenterology Research (AGR) , 2021,2 (1), 9-25.
                84. Seitz HK and Neuman MG. The history of alcoholic liver disease: from an unrecognized disease to one of the most frequent diseases in Hepatology. J. Clinical Medicine (JCM), 2021, 10, 858- 70; https://doi.org/10.3390/jcm10040858.
                85. Malnick SDH, Fisher D, Somin M, Neuman MG. Treating the metabolic syndrome by fecal transplantation- current status. Biology (Basel). 2021 May 20;10(5):447. doi: 10.3390/biology10050447. PMID: 34065241; PMCID: PMC8161223.
                86. Neuman, M.G, Mueller J, Mueller S. Non-invasive biomarkers of liver inflammation and cell death in response to alcohol detoxification. Front. Physiol.Section Gastrointestinal Sciences, 2021, 7,12:678118, doi: 10.3389/fphys.2021.678118 PMID: 34305638; PMCID: PMC8292967.
                87. Neuman M.G, Seitz H.K, Tuma P.L. ,Osna N.A., Casey, C.A. , Kharbanda, K., Cohen, L.B., Malnick S.D.H., Adhikari R., Mitra R, Singh Dagur R, Murali Ganesan, New- Aaron M, Poluektova L., Thomes P., Rasineni K, Opris M., Teschke R. Alcohol basic and translational research 15th Charles Lieber – 1st Samuel French satellite symposium. Experimental and Mol. Pathrology, February 2022.
                88. Neuman MG, Seitz HK, Teschke R, Malnick S, Johnson-Davis KL, Cohen LB, German A, Hohmann N, Moreira B, Moussa G, Opris M. Cellular, molecular, viral and clinical features of alcohol and non-alcohol induced liver disease. Current Issue in Molecular Biology, February 2022.

                Historical Articles

                1. Neuman MG, Erlinger S: Jean-Pierre Benhamou, a tribute (July 13, 1927 to September 17, 2008). Hepatology, 49(3), 709-710, 2009;doi: 10.1002/hep.22769; PMID: 19177597.
                2. Neuman MG: Obituary Charles S. Lieber 13th February 1931 – 1st March 2009, J. Hepatology, 51(3), 421-422,2009.
                3. Neuman MG: Remember Mihai Voiculescu   http://www.politicidesanatate.ro/sa-ne-amintim-de-prof-dr-mihai-voiculescu/

                Book Chapters:

                1. Scapa E, Neuman MG, Schwartz J, Magar J, Eshchar J: The mononuclear ‑ phagocyte system in the liver of elderly people. In: Wisse E, Knook DI, Deker, eds. Cells of Hepatic sinusoid. Vol. 2. The Netherlands: Kupffer Cell Foundation, 1989.
                2. Azcue M, Neuman MG, Pencharz P: What does bioelectrical impedance spectroscopy (BIS) measure? In: Ellis K, Eastman G, eds. Human Body Composition. New York: Plenum Press, 1993:121-125.
                3. Neuman MG and Tiribelli C: Drugs are they predictable in preclinical stage? Models and Techniques. In: Holoman J, Glasa J, Bechtel PR, Tiribelli C, eds. Liver and drugs ’94. Progress in Hepato-Pharmacology. Vol. 1. Bratislava, Slovakia: BoArt Publishers, 1995:24-32.
                4. Neuman MG, Cameron RG, Shear NH, Blendis LM: Electron microscopic study on antifibrotic effects of ursodeoxycholate treatment in primary biliary cirrhosis. In: Paumgartner G, Stiehl A, Keppler D, Gerok W, Leuschner U, eds. Bile Acids in Cholestasis. Ch 31. Lancaster UK: Kluwer Academic Publishers, 1999:264-279.
                5. Neuman MG, Cameron RG, Shear NH, Feuer G: Drug-induced apoptosis of skin cells and liver. In: Cameron RG, Fauer G, eds. Handbook of Experimental Pharmacology: Apoptosis modulation by drugs. Vol. 142, Chapter 13, Heidelberg: Springer Verlag Publishers, 1999:344-355.
                6. Pessayre D, Feldman G, Haouzi D, Fau A, Moreau A, Neuman MG: Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous molecules and foreign toxins). Chapter 3, In: Cameron RG, Fauer G, eds. Handbook of Experimental Pharmacology: Apoptosis modulation by drugs. Vol. 142, Chapter 3. Heidelberg: Springer Verlag Publishers, 1999:69-109. DOI: 10.1007/978-3-642-57075-9_3
                7. Neuman MG, Angulo P, Malkiewicz IM, Katz GG, Jorgensen RA, Ben-Ari Z, Schilowitz-Weiss H, Benhamou JP, Marcellin P, Lindor K: Ursodeoxycholic acid therapy affects cytokine network and plays an immunomodulatory role in patients with primary sclerosing cholangitis and primary biliary cirrhosis. In: Paumgartner G, Stiehl A, Leuschner U, eds. Bile Acids in Cholestasis: from Genetics to Therapy, Falk Symposium 129, Chapter 29. Lancaster UK: Kluwer Academic Publishers, 2002:221-235.
                8. Neuman MG Apoptosis in liver disease. Liver, a complete book on Hepato-Pancreato-Biliary Diseases, Chapter 3, Editors: Mahmun al-Mahtab, Salimur Rahman, Elsevier Reed India Ltd., India, 2009, 14-18.
                9. Neuman MG Cytokines and chemokines in liver disease. Liver, a complete book on Hepato-Pancreato-Biliary Diseases, Chapter 4, Editors: Mahmun al-Mahtab, Salimur Rahman, Elsevier Reed India Ltd., India, 2009, 19-24.
                10. Neuman MG, Schneider M, Nanau RM, Parry C, Chersich M. The relationship between alcohol consumption and human immunodeficiency virus infection and risk behaviour: A systematic literature review of high-risk groups, with a focus on South Africa; Chapter 13, In: Public Health – Social and Behavioral Health”, ISBN 979-953-307-499-2-e. InTech Open Publication, pp.243-292, May 2012. Rijeka, Croatia. http://www.intechopen.com/books/public-health-social-and-behavioral-health/the-relationship-between-alcohol-consumption-and-hiv-risk-behaviour-a-systematic-literature-review-o
                11. Nanau RM, Neuman MG. Adverse Drug Reactions to Ibuprofen. Nova Publisher, In: Carter WC, Brown BR (Eds.). Ibuprofen: Clinical Pharmacology, Medical Uses and Adverse Effects. Nova Science Publishers. Hauppauge, NY. 2013:233-274. Chapter ID 13467. ISBN 978-1-62618-659-0. https://www.novapublishers.com/catalog/product_info.php?products_id=41156
                12. Neuman MG. Hepatotoxicity: Mechanisms of Liver Injury. Chapter 7.In: New approach of liver diseases – Mechanisms and Management -A Multidisciplinary Textbook, Springer-Verlag London Ltd., Editors: Radu-Ionita F., Pyrsopoulos N.T., Jinga M., Tintoiu C., Zhonghua Sun Z., Bontas E, © Springer Nature Switzerland AG 2020.  Liver Diseases, pp.75-84. https://doi.org/10.1007/978-3-030-24432-3_7

                 

                Monograph

                1. Neuman MG, Ishay J, Zimmerman HJ, Eshchar J: Hepatotoxicity of Vespa orientalis venom sac extract. Pharmacol Toxicol, 69, supplement 1, 1991,1-36.

                Biotechnology

                Professional Articles

                Co-Editor of e-News IATDMCT (monthly)

                Global biotechnology, Clinical toxicology e-news

                IATDMCT-COMPASS-

                • Neuman MG. Antihangover – IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, January 2014.
                • Neuman MG. Alcohol interaction with drugs of use a therapeutic misadventure, IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, January 2014
                • Neuman MG The 8th Romanian Association of Medical Laboratories Annual Meeting proceeding Therapeutics and Drug Monitoring Clinical Toxicology regional meeting in Romania, IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, August 2014.
                • Neuman MG Alcohol and Chronic Diseases. Reports from the Scientific Committee of Toxicology and Drug of Abuse, December 2015, 9-11
                • Neuman MG Alcohol and Liver Damage; IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, March, 2015, 10-12.
                • Neuman MG. The first symposium on alcohol a new challenge. Rehovot, Israel; IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, May 2015, 17-18.
                • Neuman MG Alcohol and antihangover, IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, March 2016
                • Neuman MG Drugs of Use and Misuse, IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, July 2016, 6-7.
                • Neuman MG. Cannabis and viral hepatitis. Contribution of the IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, Aug. 2016, 12-16.
                • Neuman MG. Alcohol and cannabis interactions. IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, Dec 2016, 14-15.
                • Neuman MG. Pharmaco-vigillance. IATDMCT Standard of Practice Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, January 2017, 4-6.
                • Neuman MG. Hypersensitivity Syndrome Reactions. IATDMCT Standard of Practice Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, March 2017, 2-6.
                • Neuman MG Alcohol and health related consequences. IATDMCT Committee on Clinical Toxicology & Drugs of Abuse, IATDMCT Compass, Dec 2017, 1-5.
                • Neuman MG – Alcohol misuse clinical toxicology, medical and translational research. IATDMCT Compass, Dec 2017, 1-5.
                • Neuman MG Cannabis, drugs of use and misuse. IATDMCT Compass, 2018.
                • Neuman MG Cannabis controversy in epilepsy. IATDMCT Compass, 2018.
                • Neuman MG Cannabis and alcohol – IATDMCT Compass, 2018.
                • Neuman MG– Hemochromatosis and alcohol misuse. IATDMCT Compass, 2019.
                • Neuman M.G. Alcohol and hangover. IATDMCT Compass, 2020.
                • Neuman M.G. Clinical toxicology and personalized therapies. IATDMCT Compass, 2020.
                • Neuman M.G. Anttipshychotics personalized therapies. IATDMCT Compass, 2020.
                • Neuman M.G. Clinical toxicology, Indian healers and personalized therapies. IATDMCT Compass, 2021.
                • Neuman M.G. Clinical toxicology and herbal medicines. IATDMCT Compass, 2021.
                • Neuman MG: On medical cannabis. webinar.

                The Science – Liver Fibrosis Webinar

                https://wcc.on24.com/webcast/present?e=1354398&k=E22490BF53E3BA300550DB87DAB291E2

                International Editor:

                • J of Gastroenterology and Liver Disease 1994-2018
                • Romanian J. of Laboratory Medicine 2004-2010

                Guest Lead Editor:

                1. Clinical Biochemistry, 31(4), 1998: First International Symposium of Inflamed Liver: Alcohol and Cytokines, abstract book.
                2. Clinical Biochemistry, 32(7), 1999: First International Symposium: Alcohol and Cytokines in the Liver.
                3. Clinical Biochemistry, 33 (3), 2001: Second International Symposium: Alcohol and Cytokines in the Liver.
                4. International Journal of Hepatology, Special Issue on Multiple Faces of Non-Alcoholic Hepatitis, 2011
                5. Translational Research special issue – In Depth Reviews: Inflammatory Bowel Disease and Metabolomics, 2012 Jul;160(1)
                6. International Journal of Hepatology, Special Issue Inflammation and Repair: Role of Microbiome, Infection, and Nutrition, special issue of Gastroenterology Research and Practice (GIRRM), 2014
                7. International Journal of Hepatology, Special Issue Gastroenterology Research and Practice (GIRRM), 2016
                8. MDPI-Biomedicine, Experimental and Research in Liver Disease 2020-21
                9. MDPI – Cell, Drug -Induced Idiosynchratic Reactions, 2021
                10. MDPI -Cell – Opioids and alcohol Interactions 2021
                11. Frontiers in Gatroenterology 2021-2022
                12. Clinical, Translational and Basic Research on Liver Diseases 2021-2

                 

                On multiple occasions (1998, 2004, 2010, 2013), Dr. Neuman was invited by the NIAAA to Rockville, USA to work on alcohol, cancer and alcoholic liver disease, and in 2012 by the International Agency for Research on Cancer (IARC) in Lyon (France), as well as by the WHO to participate in meetings to discuss the interaction between alcohol consumption and Tuberculosis in South Africa and Alcohol as well as HIV in Argentina.

                Contact us

                Call Us

                +1-416-398-4880

                Email Us

                contact@ivdsb.com

                Our Location

                Banting Institute, 100 College Street, lab 217
                Toronto, Ontario, M5G 1L5
                CANADA

                Get in contact